A Single-Center Prospective Study on the Safety of Cold Snare Polypectomy (CSP) in Intensive Downstaging Polypectomy (IDP) for Multiple Colorectal Polyps in Familial Adenomatous Polyposis (FAP)

A Single-Center Prospective Study on the Safety of Cold Snare Polypectomy (CSP) in Intensive Downstaging Polypectomy (IDP) for Multiple Colorectal Polyps in Familial Adenomatous Polyposis (FAP) - A Single-Center Prospective Study on the Safety of Cold Snare Polypectomy (CSP) in Intensive Downstaging Polypectomy (IDP) for Multiple Colorectal Polyps in Familial Adenomatous Polyposis (FAP)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056525

Enrollment

Registered

2025-01-01

Start date

2025-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Adenomatous Polyposis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1 Patients diagnosed with Familial Adenomatous Polyposis (FAP) who are undergoing or scheduled to undergo Intensive Downstaging Polypectomy (IDP). 2 Patients who have not undergone colectomy (excluding appendectomy) or those who have undergone surgery but have at least 10 cm of the colon remaining. 3 Patients aged between 18 and 80 years at the time of consent. 4 Patients with an ECOG Performance Status (PS) of 0 or 1. 5 Patients who have provided written informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1 Presence of colorectal lesions >=10mm identified before endoscopic treatment. 2 Diagnosis of severe-type Familial Adenomatous Polyposis (FAP). 3 Pre-treatment blood tests showing a hemoglobin level <10 g/dL. 4 Presence of severe diseases in other organs. 5 Use of anticoagulants where management according to the latest guidelines of the Japan Gastroenterological Endoscopy Society is not feasible. 6 Ongoing systemic steroid therapy. 7 Undergoing chemotherapy. 8 Presence of an active infection. 9 Previous enrollment in this study. 10 Other cases deemed unsuitable for inclusion by the principal investigator or the responsible investigator.

Design outcomes

Primary

Measure	Time frame
The incidence rate of severe complications (post-procedural bleeding and gastrointestinal perforation)	—

Secondary

Measure	Time frame
All adverse events, the severity of abdominal pain on the day following the procedure, postoperative hematochezia, the need for emergency endoscopic intervention, and the occurrence of readmission	—

Countries

Japan

Contacts

Public ContactKazuki Matsuyama

Osaka International Cancer Institute Department of Gastrointestinal Oncology

matsuyama.kazuki.kyotomed@gmail.com+81-6-6945-1181

Outcome results